Upstream Bio Net Income Over Time
| UPB Stock | 27.81 1.69 6.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Upstream Bio Performance and Upstream Bio Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.40) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Upstream Bio and related stocks such as Zenas BioPharma Common, Intellia Therapeutics, and Wave Life Sciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (125.6 M) | (259.7 M) | (474.2 M) | (481.2 M) | (519 M) | (467.1 M) | (443.8 M) |
| WVE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (5.2 M) | (19.2 M) | (55.4 M) | (102 M) | (146.7 M) | (193.6 M) | (149.9 M) | (122.2 M) | (161.8 M) | (57.5 M) | (97 M) | (87.3 M) | (91.7 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| PHVS | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (9 M) | (29.6 M) | (42.7 M) | (76.3 M) | (100.9 M) | (134.2 M) | (120.8 M) | (114.8 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| NVAX | (5.5 M) | (19.4 M) | (28.5 M) | (52 M) | (82.9 M) | (156.9 M) | (280 M) | (183.8 M) | (184.7 M) | (130.1 M) | (427.5 M) | (1.7 B) | (657.9 M) | (545.1 M) | (187.5 M) | (168.7 M) | (177.2 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (29.4 M) | (50.2 M) | (60.3 M) | (90.2 M) | (88.9 M) | (80 M) | (84 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
Upstream Bio and related stocks such as Zenas BioPharma Common, Intellia Therapeutics, and Wave Life Sciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Upstream Bio financial statement analysis. It represents the amount of money remaining after all of Upstream Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Upstream Bio | UPB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 890 Winter Street, |
| Exchange | NASDAQ Exchange |
null 27.81
Check out Upstream Bio Performance and Upstream Bio Correlation. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Upstream Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.